The purpose of this study is to obtain clinical outcome data on safety and effectiveness of the directSTIM DBS system when used on-label, according to the instructions for use.

All participants will undergo bilateral implant in the subthalamic nucleus (STN) and data collected in common practice will be recorded during six months post-implant and analyzed.

directSTIM DBS Therapy for Movement Disorders is indicated for patients with disabling tremor or symptoms of Parkinson's disease.

Subjects selected to participate in the study will be Parkinson's Disease (PD) patients who are eligible for bilateral DBS for STN therapy and meet the inclusion criteria and none of the exclusion criteria.

Primary safety and effectiveness endpoints data will be collected through 6 months of follow-up. The values used for comparison are derived from a review of literature spanning from 2001 to 2019.

After completing the 6 month follow-up, subject will exit the study, and continue to be followed by their physician per usual care.

Inclusion Criteria:

• Established diagnosis of idiopathic Parkinson's Disease for 4 years or more according to the United Kingdom Parkinson's disease Brain Bank criteria, with disabling motor complications despite optimal medical treatment.
• Patient is eligible for bilateral DBS for STN therapy according to center's routine criteria and according to the directSTIM DBS system Indications for Use statement.
• Patient who is willing to provide a written informed consent.
• Patient complies with the study follow-up, in particular the follow-up visits, and other study requirements.

Exclusion Criteria:

• Patient is not eligible for DBS per center criteria.

• Patient has a cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to complete study assessments, such as:

  • Active major psychiatric disorder.
  • Dementia (MoCa Dementia Rating Scale score <26 or otherwise not capable of discernment).
  • Presence of an electrical or electromagnetic implant (e.g. cochlear implant, pacemaker).
  • Previous surgery for the treatment of Parkinson's disease.
  • Previous brain ablation procedure.
  • Epilepsy.
  • Coagulopathies.
  • Abuse of drugs or alcohol.

• Patient is participating in another clinical study that would confound data analysis.

• Patient is pregnant or nursing. As for other DBS systems, the effects of the device on an unborn child are not established.

Principal Investigator

The principal investigator will publish and/or present the data generated from the clinical investigation, following the conditions specified in the Clinical Site Agreement.

Sponsor

Sponsor will use this data for internal monitoring of product safety and performance for regulatory purposes, by performing regular updates of the safety profile and the planned interim analyses.